Conformal Medical's Breakthrough Announcement at AF Symposium
Conformal Medical, Inc. is making headlines as it prepares to showcase the results of its GLACE Study during the Annual AF Symposium. This notable event will highlight the pioneering clinical application of the company's innovative CLAAS AcuFORM Left Atrial Appendage Occlusion (LAAO) device.
GLACE Study Overview
The GLACE Study represents a significant milestone for Conformal Medical, demonstrating the potential for their new device to optimize treatment for patients with atrial fibrillation. Notably, this study involves a multicenter, single-arm approach in Europe, where device performance will be evaluated with the support of Intracardiac Echocardiography (ICE) imaging technology.
Clinical Advancements and Patient Comfort
One of the most exciting aspects of the GLACE Study is the ability to provide left atrial appendage occlusion treatment without the need for general anesthesia. Dr. Shephal Doshi, a principal investigator in the CONFORM Pivotal Trial, expressed enthusiasm about the AcuFORM device, specifically mentioning its unique foam construction that allows for immediate seal assessment under ICE guidance. This advancement not only enhances patient comfort but also improves operational efficiency during procedures.
Patient Success and Device Performance
The early results speak volumes, showcasing that a large majority of patients were treated successfully using the device. This aligns with the observations from the CONFORM Trial, enhancing confidence in the system's simplified sizing and ease of use. With more than 30 patients treated globally, the CLAAS AcuFORM device is proving to be a reliable alternative in reducing stroke risk.
Feedback from Leadership
James Reinstein, President and CEO of Conformal Medical, shared insights into the significance of the GLACE Trial. With over 420 patients randomized in the CONFORM Pivotal Trial, he highlighted the company's commitment to providing disruptive alternatives in stroke prevention. Such options are critical in enhancing the quality of care available to patients suffering from atrial fibrillation.
About Conformal Medical and its Mission
Conformal Medical, Inc. is dedicated to developing advanced medical devices that focus on preventing strokes in individuals with non-valvular atrial fibrillation. Their proprietary technologies are designed to transform left atrial appendage closure into a procedure that can be performed in a same-day, single-operator format. This innovation is a testament to the company's commitment to enhancing patient outcomes while reducing the reliance on long-term anticoagulant therapy.
Acknowledging Growing Needs in Stroke Prevention
In the broader context, it's estimated that more than six million individuals in the U.S. are affected by atrial fibrillation, an alarming statistic that places them at heightened risk for strokes. Traditional methods of stroke prevention often involve chronic oral anticoagulants, which can lead to challenges and concerns related to bleeding risks. As a result, the emergence of left atrial appendage occlusion as a viable alternative is increasingly relevant.
Frequently Asked Questions
What is the GLACE Study?
The GLACE Study is a multicenter, single-arm study assessing the performance of the CLAAS AcuFORM device for left atrial appendage occlusion.
How does the CLAAS AcuFORM device improve patient comfort?
It allows for treatment without general anesthesia and provides immediate assessment of the seal during the procedure, enhancing patient comfort.
Who is the principal investigator for the CONFORM Trial?
Dr. Shephal Doshi from Providence Saint John's Health Center is the principal investigator for the CONFORM Pivotal Trial.
What is the goal of Conformal Medical?
Conformal Medical aims to develop innovative devices that prevent strokes in patients with atrial fibrillation.
How many patients have been treated with the AcuFORM device?
Over 30 patients worldwide have been treated with the CLAAS AcuFORM device as part of ongoing trials.
